WO2016011906A1 - Utilisation de facteurs associés à la voie d'ubiquitination pour réguler le fonctionnement de cellules t auxiliaires - Google Patents

Utilisation de facteurs associés à la voie d'ubiquitination pour réguler le fonctionnement de cellules t auxiliaires Download PDF

Info

Publication number
WO2016011906A1
WO2016011906A1 PCT/CN2015/084078 CN2015084078W WO2016011906A1 WO 2016011906 A1 WO2016011906 A1 WO 2016011906A1 CN 2015084078 W CN2015084078 W CN 2015084078W WO 2016011906 A1 WO2016011906 A1 WO 2016011906A1
Authority
WO
WIPO (PCT)
Prior art keywords
cells
rorγt
usp4
helper
usp17
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/CN2015/084078
Other languages
English (en)
Chinese (zh)
Inventor
李斌
杨静
韩磊
林芳
李孔晨
李丹
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Institut Pasteur of Shanghai of CAS
Original Assignee
Institut Pasteur of Shanghai of CAS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Institut Pasteur of Shanghai of CAS filed Critical Institut Pasteur of Shanghai of CAS
Publication of WO2016011906A1 publication Critical patent/WO2016011906A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00

Definitions

  • the invention relates to the field of molecular biology and biomedicine. More specifically, the invention relates to the use of ubiquitination pathway-related factors in the regulation of helper T cell function.
  • Helper Th17 cells are newly discovered CD4-positive effector T cell subsets that promote inflammatory responses in the immune system. They participate in T cell immune responses by producing the cytokine interleukin-17 (IL-17), coordinate the body's defense against specific pathogens, and regulate tissue inflammatory responses, playing an important role in infectious diseases, autoimmunity and transplant rejection. effect.
  • the orphan nuclear receptor RORgammat (ROR ⁇ t) is important for the differentiation and function of helper Th17, and is a specific transcriptional regulator of cell differentiation. It can also regulate Th17 inflammatory response by inducing IL-17 secretion.
  • TGF- ⁇ and interleukin-6 are essential for the differentiation of Th17, and interleukin 1beta (IL-1beta) and interleukin-23 (IL-23) are also required.
  • IL-1beta interleukin 1beta
  • IL-223 interleukin-23
  • TRAF6 inhibits the differentiation of Th17.
  • a deubiquitinating enzyme or a deubiquitinating enzyme agonist for the preparation of a formulation or kit for:
  • helper T cell activity or promoting differentiation of helper T cells
  • the helper T cell activity is too low to mean that the helper T cell pro-inflammatory function is too low.
  • the disease associated with hypoxia of helper T cells is selected from the group consisting of tumors and infectious diseases.
  • the tumor is selected from the group consisting of prostate cancer, breast cancer, liver cancer, glioma, intestinal cancer, cervical cancer, non-small cell lung cancer, lung cancer, pancreatic cancer, stomach cancer, bladder cancer, skin cancer, Rhabdomyosarcoma, tongue squamous cell carcinoma, nasopharyngeal carcinoma, ovarian cancer, placental villus cancer, glioma, lymphoma, leukemia, rectal adenocarcinoma or melanoma.
  • the infectious disease is selected from the group consisting of: plague, cholera, infectious atypical pneumonia, AIDS, viral hepatitis, polio, human infection with highly pathogenic avian influenza, measles, epidemic hemorrhagic fever , rabies, epidemic encephalitis, hand, foot and mouth disease, dengue fever, anthrax, bacterial and amoebic dysentery, tuberculosis, typhoid and paratyphoid fever, epidemic cerebrospinal meningitis, whooping cough, diphtheria, neonatal tetanus, Scarlet fever, brucellosis, gonorrhea, syphilis, leptospirosis, schistosomiasis, malaria, influenza, epidemiology Mumps, rubella, acute hemorrhagic conjunctivitis, leprosy, epidemic and endemic typhus, kala-azar, echinococcosis, fil
  • the deubiquitinating enzyme is selected from one or more of the group consisting of: Ubiquitin-specific proteases (USPs) and the OUT family.
  • USPs Ubiquitin-specific proteases
  • the deubiquitinating enzyme is selected from one or more of the group consisting of USP2, USP3, USP4, USP5, USP7, USP10, USP12, USP14, USP17, USP18, USP21, USP22, USP30, USP39, USP44, YOD1, CYLD and A20; preferably, the deubiquitinating enzyme is USP2, USP4, USP17 or a combination thereof.
  • the helper T cell is selected from one or more of the group consisting of Th1, Th2, Th3, Th9, Th17, and Tfh.
  • the helper T cell cytokine is selected from one or more of the group consisting of FOXP3, IL-17A, IL-17F, IL-21, IL-23R and IL-2.
  • the "modulating the expression or activity of a helper T cell cytokine” means:
  • helper T cell cytokines selected from the group consisting of IL-17A, IL-17F, IL-21, IL-23R and/or IL-2; and/or
  • the deubiquitinating enzyme agonist is selected from one or more of the group consisting of a deubiquitinating enzyme nucleation promoter and/or an inflammatory cytokine, preferably, said The inflammatory cytokine is TGF- ⁇ .
  • the deubiquitinating enzyme nucleating promoter refers to a substance that promotes deubiquitinating enzyme entry into the nucleus or a substance that increases ubiquitinating enzyme content in the nucleus (such as IL6).
  • said increasing the stability of RORyt is achieved by deubiquitinating RORyt.
  • the deubiquitination is selected from the group consisting of: deubiquitination of the RORyt K48 site.
  • the deubiquitinating enzyme is derived from a mammal (selected from: human).
  • amino acid sequence of the USP4 is as shown in SEQ ID NO.: 2;
  • amino acid sequence of USP17 is set forth in SEQ ID NO.: 4.; and/or
  • the amino acid sequence of the USP2 is shown in SEQ ID NO.: 6.
  • the deubiquitinating enzyme is selected from the group consisting of a wild-type or mutant deubiquitinating enzyme, and is also selected from the group consisting of deubiquitin having the same function as the wild-type deubiquitinating enzyme.
  • the derivative of the deubiquitinating enzyme is selected from the group consisting of: a modified deubiquitinating enzyme molecule, an amino acid sequence homologous to a natural deubiquitinating enzyme, and having natural deubiquitinating enzyme activity Protein molecule, dimer or multimer of deubiquitinating enzyme, fusion protein containing deubiquitinating enzyme amino acid sequence.
  • the modified deubiquitinating enzyme is a PEGylated deubiquitinating enzyme.
  • the "protein molecule having an amino acid sequence homologous to the natural deubiquitinating enzyme and having natural deubiquitinating enzyme activity” means that the amino acid sequence thereof is compared with the wild type amino acid sequence (eg, for USP4) In contrast, compared to SEQ ID NO.: 2, having > 85% homology, preferably > 90% homology, more preferably > 95% homology, optimally > 98 % homology; and a protein molecule having natural deubiquitinating enzyme activity.
  • the disease associated with helper T cell activity refers to a disease or condition associated with excessive or low helper T cell activity.
  • the disease associated with helper T cell activity is selected from the group consisting of a tumor, an inflammatory response, or an autoimmune disease.
  • the preparation is selected from the group consisting of a pharmaceutical composition, a nutraceutical composition, a food composition, a vaccine composition, or an experimental reagent.
  • a deubiquitinating enzyme antagonist for the preparation of a formulation or kit for:
  • the "modulating the expression or activity of a helper T cell cytokine” means:
  • helper T cell cytokines selected from the group consisting of IL-17A, IL-17F, IL-21, IL-23R and/or IL-2; and/or
  • the disease associated with hyperactivity of helper T cells is selected from the group consisting of an inflammatory response and an autoimmune disease.
  • the inflammatory response is selected from the group consisting of: allergic inflammation, folliculitis, tonsillitis, pneumonia, hepatitis, nephritis, acne, asthma, chronic inflammation, chronic prostatitis, glomerulonephritis, hypersensitivity, Inflammatory bowel disease, pelvic inflammatory disease, reperfusion injury, vasculitis or interstitial cystitis.
  • the autoimmune disease is selected from the group consisting of: multiple sclerosis, rheumatoid arthritis, rheumatoid arthritis, rheumatic heart disease, rejection in organ transplantation, systemic lupus erythematosus, gram Autoimmune diseases such as Ron's disease, ulcerative colitis, ankylosing spondylitis, autoimmune encephalomyelitis, psoriasis, and the like, ulcerative colitis and autoimmune encephalomyelitis.
  • the deubiquitinating enzyme antagonist is selected from the group consisting of an antibody, a sh-RNA, a miRNA, an antisense oligonucleotide, a chemical inhibitor, or a combination thereof.
  • the antagonist is selected from the group consisting of: an anti-USP4 antibody, an anti-USP17 antibody, shUSP4 (short hairpin RNA), shUSP17 (short hairpin RNA), an antisense oligonucleotide against USP4 or USP17, Chemical inhibitor of USP4 or USP17.
  • nucleotide sequence of shUSP17 is set forth in SEQ ID NO.: 16.
  • the chemical inhibitor is: 4,4",5',6'-tetrahydroxy[1,1':4',1"-terphenyl]-2',3'-di Baseline phenylacetic acid (Vialinin A).
  • the regulatory T cell is selected from the group consisting of: a naturally-regulating T cell (nTreg) and an induced adaptive regulatory T cell (iTreg).
  • the disease associated with regulatory T cell activity is selected from the group consisting of cancer, viral infection, autoimmune disease, preferably autoimmune disease.
  • composition for increasing the stability of RORyt selected from the group consisting of: a deubiquitinating enzyme or a derivative thereof, and/or a deubiquitinating enzyme agonist.
  • the deubiquitinating enzyme agonist is as described above.
  • composition further comprises a pharmaceutically acceptable carrier.
  • the dosage form of the composition is selected from the group consisting of a solid formulation, a liquid formulation, preferably in the form of a dry powder or solution.
  • the composition is a pharmaceutical composition, a nutraceutical composition or a vaccine composition.
  • an isolated complex which is a complex formed by the combination of a deubiquitinating enzyme and RORyt.
  • the complex is a binary complex.
  • the complex has a molecular weight of ⁇ 80 KD; preferably the molecule of the complex The amount is ⁇ 100KD.
  • the complex has a molecular weight of from 100 KD to 500 KD; preferably from 100 KD to 200 KD.
  • a fifth aspect of the invention there is provided the use of the complex of the fourth aspect of the invention for screening a drug or a compound which promotes or inhibits deubiquitinating enzyme and ROR ⁇ t to form said complex .
  • the application when the complex is used to screen for a drug, the application includes the steps of:
  • the application when the complex is used to screen for a drug, the application includes the steps of:
  • test substance in the test group, co-incubating the test substance with (a) the complex and/or (b) deubiquitinating enzyme and ROR ⁇ t; and setting a control group without the substance to be tested;
  • a deubiquitinating enzyme antagonist for the manufacture of a medicament for the treatment of systemic lupus erythematosus or rheumatic heart disease.
  • the deubiquitinating enzyme antagonist is selected from the group consisting of an antibody, a sh-RNA, a miRNA, an antisense oligonucleotide, a chemical inhibitor, or a combination thereof.
  • the antagonist is selected from the group consisting of: an anti-USP4 antibody, an anti-USP17 antibody, shUSP4 (short hairpin RNA), shUSP17 (short hairpin RNA), an antisense oligonucleotide against USP4 or USP17, Chemical inhibitor of USP4 or USP17.
  • nucleotide sequence of shUSP17 is set forth in SEQ ID NO.: 16.
  • the chemical inhibitor is: 4,4",5',6'-tetrahydroxy[1,1':4',1"-terphenyl]-2',3'-di Baseline phenylacetic acid (Vialinin A).
  • a composition comprising one or both components selected from the group consisting of IL-6 and TGF ⁇ for the preparation of a reagent for promoting deubiquitinating enzyme entry into the nucleus.
  • the deubiquitinating enzyme is selected from one or more of the group consisting of: Ubiquitin-specific proteases (USPs) and the OUT family.
  • USPs Ubiquitin-specific proteases
  • the deubiquitinating enzyme is selected from one or more of the group consisting of USP2, USP3, USP4, USP5, USP7, USP10, USP12, USP14, USP17, USP18, USP21, USP22, USP30, USP39, USP44, YOD1, CYLD and A20; preferably, the deubiquitinating enzyme is USP2, USP4, USP17 or a combination thereof.
  • the agent that promotes deubiquitinating enzyme entry into the nucleus includes an agent that promotes deubiquitinating enzyme entry into the nucleus and/or an agent that increases ubiquitination enzyme content in the nucleus.
  • the autoimmune disease is selected from the group consisting of: multiple sclerosis, rheumatoid arthritis, rheumatoid arthritis, rheumatic heart disease, rejection in organ transplantation, systemic lupus erythematosus Autoimmune diseases such as Crohn's disease, ulcerative colitis, ankylosing spondylitis, autoimmune encephalomyelitis, psoriasis, preferably ulcerative colitis and autoimmune encephalomyelitis.
  • FIG 1 shows that USP4 is highly expressed in Th17 and affects the stability of its important transcription factor ROR ⁇ t.
  • FIG. 1A Figure 1B.
  • FACS Flow cytometry
  • CD45RA+CD4+naive T cells from human peripheral blood cells (PBMC), and different helper T cells were obtained under different helper T cell induction conditions.
  • shCK is a control in which the expression of the gene has no effect
  • shUSP4-1 and shUSP4-2 are the experimental groups in which the USP4 gene is specifically knocked down.
  • Fig. 1C Fig. 1D.
  • Naive T cells were induced for 7 days under Th17 induction conditions, and incubated with USP4 gene knockdown virus (puromycin resistance) overnight. After transfusion, 72 days after infection, puromycin was added for one week, and cells were collected for q. -RTPCR and immunoblotting with the corresponding antibodies showed that knockdown of USP4 can affect the stability of ROR ⁇ t protein level, but has no effect on its mRNA level, indicating that the regulation of ROR ⁇ t by USP4 may be the level of post-translational modification.
  • FIG. 2 shows that USP4 affects the stability of ROR ⁇ t by binding and deubiquitination, wherein
  • FIG. 1 Naive T cells were induced for 7 days under Th17 induction, then cells were harvested and lysed by RIPA buffer, then co-immunoprecipitated with USP4 antibody, and then immunoblotted with the corresponding antibodies. The results showed that USP4 and ROR ⁇ t were in Th17. Direct interaction; IP-USP4 indicates that USP4 protein is enriched in cell lysate with USP4 specific recognition antibody, and INPUT indicates supernatant of untreated cell lysate, the same below;
  • Figure B Co-transformation of HA-USP4 or its enzyme-deficient mutant Ser311A mutant with FLAG-ROR ⁇ t into HEK 293T cells, and treatment of cells with inhibitory protein synthesis reagent (CHX (Cycloheximide from microbial) cycloheximide) 36 h later At 4,8,12h, the cells were collected and lysed, and then HA and FLAG and other corresponding antibodies were used for immunoblot analysis. The results showed that wild type USP4 can prolong the half-life of ROR ⁇ t protein, but the activity of the enzyme mutant is weak.
  • CHX Cycloheximide from microbial cycloheximide
  • HA-USP4 represents the HA-tagged USP4 protein expressed by linking the HA tag and the USP4 gene
  • FLAG-ROR ⁇ t represents the FLAG-tagged ROR ⁇ t protein expressed by linking the FLAG tag and the ROR ⁇ t gene together
  • WT indicates wild type.
  • CA indicates that the cysteine at position 311 of the amino acid sequence of USP4 is mutated to alanine, and the protein conformation and hydrophobicity are changed, and the enzyme activity is decreased, the same below;
  • Figure C HA-USP4 with FLAG-ROR ⁇ t and His-ubiquitin or its mutant (Lys48only, all lysine on ubiquitin is mutated to arginine, except for the 48th retention, Lys63only All lysines on ubiquitin were mutated to arginine, except for the 63rd retention), which were co-transformed into HEK 293T cells.
  • Cells were harvested 48h and denatured with 8M urea and then bound with nickel beads (beads).
  • His ie His-pull down assay
  • USP4 his-pull down assay
  • His-ubi represents a His-tagged ubiquitin protein expressed by linking six His-tags to a ubiquitin gene
  • FIG. D FLAG-ROR ⁇ t-Jurkat stable strain was stimulated with USP4 inhibitor (20 nM) for 4 hours, and without stimulation and FLAG-Jurkat control, cells were harvested and lysed and then co-immunoprecipitated with FLAG, and then used. Immunoblot analysis of endogenous ubiquitin antibodies and other corresponding antibodies showed that inhibition of endogenous USP4 enzyme activity by the chemical reagent vialinin A affected the level of ubiquitination of ROR ⁇ t.
  • FIG. 3 shows that USP4 promotes ROR ⁇ t-induced transcription and production of interleukin-17, wherein
  • FIG. 1 IL-17A luciferase promoter reporter gene (-600-0bp), Renilla (control) and different gradients of HA-USP4 and FLAG-ROR ⁇ t co-transformed into HEK 293T cells, 48h collection of cells with fluorescein After the enzyme reporter lysate was lysed, the supernatant was added to the reaction solution and the blocking solution, and the fluorescence value was measured. Then, HA and FLAG and other corresponding antibodies were used for immunoblot analysis, and the results showed that USP4 mediated the transcription of IL-17A by ROR ⁇ t. Promotion is USP4 gradient dependent;
  • FIG. B C. HEK 293T cells were transfected into USP4 gene knockdown plasmid (puromycin resistance). After transfection, 72 hours after transfection, puromycin was added for one week. Cells were passaged and transferred to IL-17A luciferase. The promoter reporter gene (-600-0bp), renilla (control) and FLAG-ROR ⁇ t were collected. After 48 hours, the cells were collected for fluorescence measurement and immunoblotting with the corresponding antibody. The results showed that the endogenous USP4 was knocked down, and ROR ⁇ t was mediated. The transcription level of IL-17A is inhibited;
  • FIG. D E. IL-17A luciferase promoter reporter gene (-600-0bp), renilla (control) were transferred into FLAG-ROR ⁇ t-Jurkat or FLAG-Jurkat cells, and PMA and inomycin (muscle) were added after 44h. (P/I, simulated TCR signal), after 4 hours, the cells were collected and lysed with luciferase reporter lysate, and the supernatant was added to the reaction solution and the blocking solution to measure the fluorescence value, and then USP4 and FLAG and other corresponding The antibody was used for immunoblot analysis. The results showed that the addition of USP4 inhibitor in the T cell stably inhibited ROR ⁇ t-mediated transcription of IL-17A promoted by the TCR signaling pathway.
  • Figure 4 shows that IL-6 promotes ROR ⁇ t-induced interleukin-17 transcription and production by altering the nuclear localization of USP4,
  • FIG. 1 IL-17A luciferase promoter reporter gene (-600-0bp), renilla (control) was transferred into FLAG-ROR ⁇ t-Jurkat or FLAG-Jurkat cells, and fresh juice was added after 36h (P/ I) overnight, after adding TGF ⁇ (1 ng/ml) and IL-6 (20 ng/ml) for 8 hours, the cells were collected and lysed with luciferase reporter lysate, and the supernatant was added to the reaction solution and the blocking solution to measure the fluorescence value. Then USP4 and FLAG and other corresponding antibodies were used for immunoblot analysis. The results showed that the promotion of ROR ⁇ t-mediated IL-17A transcription by TGF ⁇ and IL-6 can be inhibited by USP4 (enzyme activity inhibitor (USP4i)).
  • USP4 enzyme activity inhibitor
  • FIG. B C. FLAG-ROR ⁇ t-Jurkat or FLAG-Jurkat cells were incubated with USP4 gene knockdown virus (puromycin resistance) overnight. After transfusion, 72 days after infection, add puromycin for one week and then transfer to IL-17A. The luciferase promoter reporter gene (-600-0bp), renilla (control), 36h later, fresh liquid was added (P/I) overnight, TGF ⁇ (1ng/ml) and IL-6 (20ng/ml) were added. After 8 hours of stimulation, the cells were collected and lysed with luciferase reporter lysate. The supernatant was added to the reaction solution and the blocking solution, and the fluorescence was measured.
  • USP4 gene knockdown virus puromycin resistance
  • FIG. D FLAG-ROR ⁇ t-Jurkat cells were added (P/I) overnight, cells were harvested by adding TGF ⁇ (1 ng/ml) and IL-6 (20 ng/ml) or simultaneously with USP4 inhibitor for 8 h, and then lysed.
  • TGF ⁇ 1 ng/ml
  • IL-6 20 ng/ml
  • USP4 inhibitor for 8 h
  • ubiquitination the reduction of ROR ⁇ t ubiquitination by TGF ⁇ and IL-6 can be inhibited by the activity of USP4.
  • Agent offset ubi is the abbreviation of ubiquitin protein
  • FIG. E F. FLAG-ROR ⁇ t-Jurkat cells were added (P/I) overnight, stimulated with different treatments of TGF ⁇ (1 or 5 ng/ml) and IL-6 (20 ng/ml) for 8 h. The cells were harvested and fixed with paraformaldehyde. After 30 min, 1% BSA was blocked for 1 h and then incubated with USP4 antibody for 1 h. After washing three times with PBS, the fluorescent secondary antibody (red) was incubated, DAPI (blue) was incubated for 1 h, and PBS was washed three times for immunofluorescence experiments.
  • the bar graph is used to represent the nuclear shuttle ratio of USP4 by the value of blue light (indicating the nucleus) compared with red light (representing the nuclear and cytoplasmic USP4).
  • the results show that the effects of TGF ⁇ and IL-6 on ROR ⁇ t play a role in affecting the nuclear localization of USP4 (in the figure, it can be seen that a single high-concentration TGF ⁇ or a single plus IL-6USP4 is relatively abundant, and TGF ⁇ and IL-6USP4 are added simultaneously.
  • the nuclear reduction increases the amount of USP4 in the nucleus and promotes the deubiquitinating enzyme into the nucleus.
  • Figure 5 shows that USP4 inhibitors can impair Th17 cell differentiation and are highly expressed in Th17-dominant rheumatic heart disease samples
  • FIGS. A, B and C People T cells were sorted by BD FACS AriaII flow cytometry, and treated with DMSO or USP4 inhibitor (1 uM, 2 uM, inhibitor (USPi) for Vialinin A) for 7 days under Th17 induction conditions. -PCR and flow cytometric analysis by PE-ROR ⁇ t, APC-FOXP3 and Percp/cy5.5-IL-17 antibodies, the results showed that the addition of USP4 inhibitors during the initial phase of Th17 differentiation and the whole process can be obvious The inhibition of Th17 differentiation efficiency is due to a decrease in the stability of ROR ⁇ t or an increase in the expression level of FOXP3 during differentiation.
  • Figure D Enrichment of CD4 + T cells with magnetic beads in peripheral blood of rheumatic heart disease and healthy controls, followed by qRT-PCR analysis with specific primers, showing up-regulation of USP4 and IL in samples from patients with rheumatic heart disease
  • the up-regulation of -17 has important correlations, explaining that under the inflammatory conditions of autoimmune diseases in vivo, USP4 may be used as a specific drug target for the treatment of diseases, and its specific chemical inhibitors can be used as new therapeutic drugs.
  • Figure 6 shows deubiquitinating enzymes USP2, USP4, USP12, USP14, USP39 enhancing ROR ⁇ t-mediated transcriptional activity of the Il17a promoter, and USP2, USP4, USP17 are capable of effectively removing ubiquitination of ROR ⁇ t, wherein
  • FIG. 1 Myc-USPs (USP with MYC tag expressing MYC tag and different USP genes, ie deubiquitinating enzyme protein), HA-ROR ⁇ t, Il17a promoter and ⁇ -galactoside
  • the enzyme reporter gene was co-transfected into human renal epithelial cells HEK 293T cells. After harvesting the cells 36 hours later, the effect of deubiquitinating enzyme on ROR ⁇ t-mediated transcriptional activity was observed by luciferase reporter gene assay;
  • FIG. 1 Myc-DUBs (DUBs with MYC tags expressing MYC tags and different DUB genes, ie deubiquitinating enzyme proteins), FLAG-ROR ⁇ t and HA-Ubiquitin (representing HA tags and The HA-tagged ubiquitin protein expressed by the ubiquitin gene was co-transfected into HEK 293T cells, and the cells were collected 48h later, lysed by RIPA buffer, and then co-immunoprecipitated with anti-Flag antibody, and then immunoblotted with the corresponding antibody. Detection
  • FIG. 1 Il17a promoter and ⁇ -galactosidase reporter gene, Myc-USP17 and Flag-ROR ⁇ t co-transfected human renal epithelial cells HEK 293T cells, harvested cells after 36 hours, lysed cells with reporter lysate, and added reaction The effect of substrate detection related activity;
  • Panel D The Il17a promoter and the Renilla reporter gene, Myc-USP17 were electrotransformed in the Flag-ROR ⁇ t stable transfectant, and were incubated with PMA and Inomycin for 12 hours after 36-48 hours, and were sampled by dual luciferase reporter assay.
  • FIG. 7 shows the USP17 and ROR ⁇ t interactions
  • FIG. 1 USP17 interacts with ROR ⁇ t.
  • Flag-ROR ⁇ t and Myc-USP17 are co-transformed into HEK 293T cells in six-well plates. Cells are harvested 48 hours later and 1 ⁇ g of anti-Flag or anti-Myc monoclonal is added after lysis. The antibody was precipitated and subjected to immunoblot analysis by monoclonal antibodies against Myc or anti-Flag. The expression levels of ROR ⁇ t and USP17 in cell lysates were also analyzed by immunoblotting;
  • Figure B Naive T cells were induced for 7 days under Th17 induction conditions, and then the cells were harvested and lysed by RIPA buffer, then co-immunoprecipitated with USP17 antibody, and then immunoblotted with the corresponding antibody;
  • FIG. 1 Schematic diagram of the ROR ⁇ t domain
  • Panel D USP17 can interact with two domains of RORyt.
  • a total of Flag-tagged ROR ⁇ t three truncated mutants and USP17 were transfected into 293T cells, cells were harvested 48 hours later, lysed, precipitated with anti-Myc monoclonal antibody, and immunoblotted with anti-Myc or anti-Flag monoclonal antibody. .
  • the expression levels of ROR ⁇ t mutant and USP17 in cell lysates were also analyzed by immunoblot.
  • Figure 8 shows USP17 stable ROR ⁇ t
  • FIG. 1 USP17 enhances ROR ⁇ t stability.
  • the same dose of Flag-ROR ⁇ t co-transfects human renal epithelial cells HEK 293T cells with increasing doses of Myc-USP17 and Myc-USP17C89S, and harvests cells 48 hours later.
  • USP17 in cell lysates And ROR ⁇ t expression levels were analyzed by immunoblotting;
  • FIG. 1 USP17 stabilizes ROR ⁇ t and extends its half-life.
  • Myc-USP17 and Flag-ROR ⁇ t co-transform human renal epithelial cells HEK 293T cells, and treated with protein synthesis inhibitor CHX for a period of time (0h, 4h, 8h, 12h) before harvesting cells, USP17 and ROR ⁇ t expression levels in cell lysates Immunoblot analysis.
  • Figure C Quantitative analysis of the intensity of ROR ⁇ t protein bands treated with different treatments at different times in 8B using Image J image analysis software.
  • Figure 9 shows the ubiquitination of USP17 to ROR ⁇ t K48, where
  • FIG. 1 Myc-ROR ⁇ t and Flag-Ubiquitin were co-transformed into 293T cells. After 48 hours, the cells were harvested and treated with pre-protein degradation inhibitor MG132 (20 um/ml) for 3 h, precipitated by anti-Myc monoclonal antibody, and then Monoclonal antibodies against Myc or anti-Flag were subjected to immunoblot analysis, and the expression level of ROR ⁇ t in cell lysates was also analyzed by immunoblotting;
  • Figure B Transfection of Flag-ROR ⁇ t, Myc-USP17, Myc-USP17C89S and His-Ubiquitin in 293T cells, cells were collected 48 hours later, and MG132 (20 um/ml) was collected for 3 h before harvesting, using Ni-NTA nickel chelate The resin was purified and precipitated, and then subjected to immunoblot analysis by anti-Myc, anti-Flag and anti-His monoclonal antibodies. The expression levels of ROR ⁇ t, ubiquitin and USP17 in the cell lysate were also analyzed by immunoblotting.
  • USP17 is capable of ubiquitinating K48-related ubiquitin
  • 293T cells are transfected with Flag-ROR ⁇ t, Myc-USP17 and His-Ubiquitin mutants K63only and K48only
  • cells are harvested 48 hours later, and pre-cell MG132 is collected ( 20 um/ml) treatment for 3 hours, purification of the precipitate using Ni-NTA nickel chelate resin, and immunoblot analysis by anti-Myc, anti-Flag and anti-His monoclonal antibodies, expression of ROR ⁇ t, ubiquitin and USP17 in cell lysate Levels were also analyzed by immunoblotting.
  • Figure 10 shows that down-regulation of USP17 in Th17 cells reduces the protein level of ROR ⁇ t and affects the transcription level of Th17-associated cytokines, wherein
  • FIG. 1 Specific shRNAs of Myc-USP17 and USP17 were simultaneously transduced in 293T cells, cells were harvested 48 hours later, and lysed and immunoblotted by anti-Myc monoclonal antibody to detect shRNA knockout efficiency;
  • FIG. B Figure B. DR8.9, shRNA, VSVG three-plasmid system packaging lentivirus, collecting virus after 36-48 hours, infecting Flag-ROR ⁇ t stably transfected cells, and constructing shRNA to carry puromycin resistance, so after one week of screening with puromycin, After cell lysis, the expression of related proteins was detected by immunoblotting with anti-ROR ⁇ t and anti-USP17 antibodies.
  • FIG. DR8.9 shRNA, VSVG three-plasmid system packaged lentivirus, collected virus after 36-48 hours, infected with Th17 cells differentiated in vitro, constructed by shRNA carrying puromycin resistance, so after one week of screening with puromycin, After cell lysis, the expression of related proteins was detected by immunoblotting with anti-ROR ⁇ t antibody and anti-USP17 antibody.
  • Figure D Purification of RNA by Th17 cells after one week of puromycin screening and inversion of cDNA, and the transcription levels of related genes (USP17, IL-17A, IL-17F, IL-23R) were detected by real-time quantitative PCR.
  • Figure 11 shows that USP17 transcription levels are significantly elevated in patients with systemic lupus erythematosus (SLE),
  • FIG. 1 Peripheral venous blood from patients with systemic lupus erythematosus diagnostic criteria and healthy controls.
  • CD4 + T cell enrichment kit was used to isolate CD4 + T cells, extract RNA and reverse cDNA, and detect related genes by real-time quantitative PCR. ;
  • Figure C Grouping patients according to the SLE patient disease activity index and analyzing changes in USP17 transcript levels in the active and inactive groups.
  • Figure 12 shows the therapeutic effect of Vialinin A on its own encephalomyelitis, wherein
  • Figure A shows the experimental flow chart.
  • mice were injected with pertussis toxin in the tail vein, and the MOG peptide was subcutaneously immunized to induce experimental autoencephalomyelitis.
  • Vialinin A (inhibitor of USP4) was intraperitoneally injected on days 9, 12, and 15, respectively, and the same amount of solvent (PBS containing 5% DMSO) was injected into the control group. The disease status of the mice was observed, and the mice were sacrificed on the 25th day for experimental analysis.
  • Panel B shows the disease score. The results showed that the control group started on the 10th day, and then the disease developed rapidly and entered the plateau on the 19th day. There was no significant difference between the drug-administered group and the control group in the early stage of the disease. In the 18 to 21 days with severe disease, the drug-administered group was significantly better than the control group.
  • deubiquitinating enzymes have a significant effect on up-regulating the stability of ROR ⁇ t, thereby upregulating the activity of T helper cells and their differentiation and up-regulating the helper T cell cytokines. Expression, on the basis of which the present invention has been completed.
  • ubiquitinating enzymes Approximately 100 deubiquitinating enzymes have been discovered to date, the main function of which is to hydrolyze ubiquitin molecules from proteins linked to ubiquitin by hydrolyzing the carboxy terminal residues on ubiquitin. According to their structural and functional characteristics, they can be divided into five families: Ubiquitin C-terminal hydrolases (UCHs), Ubiquitin-specific proteases (USPs), and ovarian tumor-associated proteases. (Ovarian tumor, OTU), Ataxin-3 (containing Josephin domain), MPN (+)/JAMM protease (JAB1/MPN/Mov34 metlloenzyme domain zinc-dependent metalloprotease family).
  • UCHs Ubiquitin C-terminal hydrolases
  • USPs Ubiquitin-specific proteases
  • ovarian tumor-associated proteases Ovarian tumor, OTU
  • Ataxin-3 containing Josephin domain
  • MPN (+)/JAMM protease JAB1/
  • deubiquitinating enzyme functions include: 1 deubiquitinating enzyme activates ubiquitin proprotein by means of co-translation. Ubiquitin is expressed as a proprotein and fused to a ribosomal protein or linear polyubiquitin, and the polyubiquitin gene product must also remove excess residues at the carbon end to activate ubiquitin. 2 Deubiquitination can recover ubiquitin captured by small cell nucleophiles containing a thiol ester intermediate, thereby participating in ubiquitination of the protein. 3 Deubiquitinating enzyme reversely removes ubiquitination or ubiquitin-like modification of the target protein.
  • the ubiquitination of the ubiquitinating enzyme antagonist protein is similar to the action of phosphatase in the kinase/phosphatase regulatory pathway. 4 Deubiquitinase is responsible for the regeneration of monoubiquitin from non-anchored polyubiquitin chains.
  • the deubiquitinating enzyme USP4 specifically removes the monomeric or polyubiquitination of the substrate protein and prevents it from entering the proteasome to degrade or affect its function, thereby affecting tumorigenesis, apoptosis, immune response and the like.
  • TGF ⁇ R1 tumor growth factor receptor
  • the deubiquitinating enzyme USP17 interacts with SDS through the HABM domain to inhibit tumor cell growth. It has recently been discovered that USP17 is capable of modulating viral-induced type I interferon signaling by deubiquitination of RIG-1 and MDA5. Deletion of USP17 prevents normal cytoskeletal rearrangement and chemokine-induced Rho GTPase membrane localization, therefore, USP17 is also essential for Rho GTPase localization during normal cell movement. In conclusion, the effect of USP17 on apoptosis, cell proliferation, and cell cycle progression is an important factor in maintaining cell homeostasis.
  • Rheumatic heart disease is caused by infection with streptococcus, a component of streptococcal cell wall is similar to the connective tissue of the human heart valve, and then develops into a disease that destroys the heart valve, and systemic lupus erythematosus is also a common clinical disease.
  • the autoimmune diseases, the clinical manifestations are complex and changeable, the disease is protracted and difficult to heal, and the current treatment strategies are still scarce.
  • Current research indicates that the balance of helper Th17 and regulatory Treg is critical for the development and treatment of rheumatic heart disease.
  • helper T cells and transcription factors ROR ⁇ t The immunological activity of helper T cells and immunotherapy based on helper T cells are essential. This provides new research propositions and challenges for translating basic immunization research into clinical research and understanding human-specific autoimmune diseases such as multiple sclerosis.
  • USP4 and USP17 were significantly up-regulated in the blood samples of these two types of patients, respectively, and it is expected to become a new therapeutic target.
  • the deubiquitinating enzyme of the present invention is selected from the group consisting of a wild-type or mutant deubiquitinating enzyme, and is also selected from: an active fragment of a deubiquitinating enzyme having the same function as a wild-type deubiquitinating enzyme. Or derivatization of derivatives of ubiquitinating enzymes.
  • the derivative of the deubiquitinating enzyme is selected from the group consisting of: a modified deubiquitinating enzyme molecule, an amino acid sequence homologous to a natural deubiquitinating enzyme, and having natural deubiquitinating enzyme activity Protein molecule, dimer or multimer of deubiquitinating enzyme, fusion protein containing deubiquitinating enzyme amino acid sequence.
  • the deubiquitinating enzyme "USP4" or “USP17” refers to a protein which has (a) and (Wang L, et al. J Virol. 2013), (de la Vega M, et The "USP4" or “USP17” substantially identical amino acid sequences described in al. Nat Commun. 2011) and (b) have the same biological activity as the native "USP4" or “USP17” and have substantially the same amino acid sequence.
  • USB4 or “USP17” of the present invention includes, but is not limited to, human “USP4" or “USP17”, recombinant human “USP4" or “USP17”, murine “USP4" or “USP17” and/or recombinant mouse “USP4" “or “USP17”.
  • nucleotide sequence of USP4 is as set forth in SEQ ID NO.
  • the amino acid sequence of USP4 is:
  • nucleotide sequence of USP17 is set forth in SEQ ID NO.
  • the amino acid sequence of USP17 is:
  • the nucleotide sequence of USP2 is shown in SEQ ID NO.: 5.
  • the amino acid sequence of USP2 is:
  • substantially identical amino acid sequence refers to a difference in sequence or caused by one or more amino acid changes (deletion, addition, substitution), but such alteration does not substantially reduce its biological activity.
  • Any deubiquitinating enzyme that meets the "substantially identical" requirement is included in the present invention, whether it is glycosylated (ie, derived from a natural or eukaryotic expression system) or non-glycosylated ( That is, derived from prokaryotic expression systems or chemically synthesized).
  • Deubiquitinating enzymes also include PEGylated deubiquitinating enzymes as well as covalently modified deubiquitinating enzyme proteins.
  • PEG polyethylene glycols
  • various activated polyethylene glycols (PEG) having a molecular weight of 5,000 to 100,000 can be used to polymerize IL-17 to prolong its half-life.
  • PEG polyethylene glycols
  • the deubiquitinating enzyme of the present invention can be cloned and expressed by genetic recombination techniques.
  • Host cells for expression include prokaryotic cells, yeast cells, or higher eukaryotic cells.
  • eukaryotic cells such as filamentous fungi or yeast are equally suitable for expressing or cloning the interleukin-17 of the present invention.
  • the host cell of the deubiquitinating enzyme of the present invention for expressing glycosylation is derived from a multicellular organism. Examples of invertebrate cells include insect cells such as Drosophila S2 and Spodoptera Sf9, plant cells. Examples of suitable mammalian host cells include Chinese hamster ovary cells (CHO), COS cells. One of ordinary skill in the art will know how to select a suitable host cell.
  • the above host cells are transfected or transformed by a deubiquitinating enzyme expression vector or a cloning vector and cultured in a conventional nutrient medium, which is modified to be suitable for inducing a promoter and selectivity.
  • a transforming transformant or amplifying a deubiquitinating enzyme-encoding gene sequence Selection of culture conditions such as medium, temperature, pH, etc. will be known to those of ordinary skill in the art. General principles, protocols, and techniques for how to maximize cell culture fertility can be found in Mammalian Cell Biotechnology: a Practical Approach, M. Butler, ed. (IRL Press, 1991) and Sambrook et al., supra.
  • the deubiquitinating enzyme of the present invention can be directly expressed not only by genetic recombination, but also by forming a fusion polypeptide with a heterologous polypeptide, which may be a signal sequence located at the N-terminus of the mature protein or polypeptide, or may be located in the mature protein. Or other polypeptide fragments having a specific cleavage site at the N-terminus of the polypeptide.
  • the DNA sequence encoding the deubiquitinating enzyme dimer or fusion protein of the present invention can be fully synthesized.
  • the DNA sequence encoding the de-ubiquitinating enzyme first monomer and/or the deubiquitinating enzyme second monomer can also be obtained by PCR amplification or synthesis, and then spliced together to form a fusion protein encoding the present invention. DNA sequence.
  • the deubiquitinating enzyme dimer coding sequence can be engineered, for example, using a host cell-preferred codon to eliminate sequences that are not conducive to gene transcription and translation.
  • a host cell-preferred codon to eliminate sequences that are not conducive to gene transcription and translation.
  • the yeast cell or mammalian cell-preferred codon can be used, and the deubiquitinating enzyme dimer gene can be detected by computer DNA software, and the sequence which is not conducive to gene transcription and translation in the gene is excluded, including Intron cleavage site, transcription termination sequence, and the like.
  • the DNA sequence encoding the novel fusion protein of the present invention After obtaining the DNA sequence encoding the novel fusion protein of the present invention, it is ligated into a suitable expression vector and transferred to a suitable host cell. Finally, the transformed host cells are cultured, and the novel fusion protein of the present invention is obtained by isolation and purification.
  • vector includes plasmids, cosmids, expression vectors, cloning vectors, viral vectors, and the like.
  • various carriers known in the art such as commercially available carriers can be used.
  • a commercially available vector is selected, and then a nucleotide sequence encoding a novel fusion protein of the present invention is operably linked to an expression control sequence to form a protein expression vector.
  • operably linked refers to a condition in which portions of a linear DNA sequence are capable of affecting the activity of other portions of the same linear DNA sequence. For example, if a signal peptide DNA is expressed as a precursor and is involved in the secretion of a polypeptide, then the signal peptide (secretion leader sequence) DNA is operably linked to the polypeptide DNA; if the promoter controls the transcription of the sequence, then it is operably linked to A coding sequence; if the ribosome binding site is placed at a position that enables translation, then it is operably linked to the coding sequence.
  • “operably linked to” means adjacent, and for secretory leader sequences means adjacent in the reading frame.
  • the term "host cell” includes prokaryotic cells and eukaryotic cells.
  • prokaryotic host cells include Escherichia coli, Bacillus subtilis and the like.
  • eukaryotic host cells include yeast cells, insect cells, and mammalian cells.
  • the host cell is a eukaryotic cell, more preferably a mammalian cell.
  • the cell After obtaining the transformed host cell, the cell can be cultured under conditions suitable for expression of the fusion protein of the present invention to express the fusion protein.
  • the expressed fusion protein is then isolated.
  • the orphan nuclear receptor RORgammat (ROR ⁇ t) is important for the differentiation and function of helper Th17, and is a specific transcriptional regulator of cell differentiation. It can also regulate Th17 inflammatory response by inducing IL-17 secretion.
  • the presence of an intermediate Foxp3 + ROR ⁇ t + cell was also found in other helper T cells, and this intermediate appeared in the NOD mouse T cell before inflammation and could be expanded without differentiation, so It is speculated that it may be a temporary cell population before differentiation into Treg/Th17. The direction in which this temporary cell population is differentiated may depend on the cellular microenvironment in which it is located.
  • treating refers to the administration of interleukin-17 of the present invention to a subject in need of treatment for the purpose of curing, alleviating, ameliorating, alleviating, affecting the disease, symptoms, and disease predisposition of the subject.
  • terapéutica subject refers to rats, humans, and other mammals.
  • terapéuticaally effective amount refers to an amount of a deubiquitinating enzyme or derivative thereof, a deubiquitinating enzyme agonist or antagonist capable of achieving therapeutic purposes in a subject.
  • a deubiquitinating enzyme agonist or antagonist capable of achieving therapeutic purposes in a subject.
  • therapeutically effective amount may follow the route of administration of the ubiquitinating enzyme or derivative thereof, the deubiquitinating enzyme agonist or antagonist, the pharmaceutical excipients used, and other drugs. The combination of medications varies.
  • the pharmaceutical composition of the present invention comprises a deubiquitinating enzyme of the present invention or a derivative thereof, a deubiquitinating enzyme agonist or antagonist (active ingredient), and a pharmaceutically acceptable excipient or a safe or effective amount Carrier.
  • safe, effective amount it is meant that the amount of active ingredient is sufficient to significantly improve the condition without causing serious side effects.
  • the pharmaceutical compositions contain from 0.001 to 1000 mg of active ingredient per dose, preferably from 0.05 to 300 mg of active ingredient per dose, more preferably from 0.5 to 200 mg of active ingredient per dose.
  • the active ingredient of the present invention and a pharmaceutically acceptable salt thereof can be formulated into various preparations containing the active ingredient of the present invention or a pharmacologically acceptable salt thereof in a safe and effective amount and a pharmacologically acceptable form.
  • Agent or carrier By "safe, effective amount” it is meant that the amount of active ingredient is sufficient to significantly improve the condition without causing serious side effects.
  • the safe and effective amount of the active ingredient is determined according to the specific conditions such as the age, condition, and course of treatment of the subject.
  • “Pharmacologically acceptable excipient or carrier” means: one or more compatible solid or liquid fillers or gel materials which are suitable for human use and which must be of sufficient purity and of sufficiently low toxicity .
  • “compatibility” it is meant herein that the components of the composition are capable of intermixing with the compounds of the invention and with each other without significantly reducing the potency of the compound.
  • Examples of pharmaceutically acceptable excipients or carriers are cellulose and its derivatives (such as sodium carboxymethylcellulose, sodium ethylcellulose, cellulose acetate, etc.), gelatin, talc, solid lubricants (such as stearic acid, magnesium stearate), calcium sulfate, vegetable oil (such as soybean oil, sesame oil, peanut oil, olive oil, etc.), polyol (such as propylene glycol, glycerin, mannitol, sorbitol, etc.), emulsifier (such as ), a wetting agent (such as sodium lauryl sulfate), a coloring agent, a flavoring agent, a stabilizer, an antioxidant, a preservative, a pyrogen-free water, and the like.
  • cellulose and its derivatives such as sodium carboxymethylcellulose, sodium ethylcellulose, cellulose acetate, etc.
  • gelatin such as sodium carboxymethylcellulose, sodium ethylcellulose, cellulose
  • composition of the present invention When the composition of the present invention is administered, it can be administered orally, rectally, parenterally (intravenously, intramuscularly or subcutaneously) or topically.
  • compositions of the invention may be administered alone or in combination with other pharmaceutically acceptable compounds.
  • microcapsules containing the composition of the present invention can be used for sustained release administration of the active ingredient of the present invention.
  • the microcapsule sustained release drug delivery technology of recombinant protein has been successfully applied to recombinant human growth hormone (rhGH), recombinant human interferon (rhIFN), interleukin-2 and MNrgp120 (Johnson et al., Nat. Med., 2:795- 799 (1996); Yasuda, Biomed. Ther 27: 1221-1223 (1993); WO 97/03692, WO 96/40072, WO 96/07399; US Pat. No. 5,654,010.
  • the sustained release preparation of the active ingredient of the present invention can be prepared using a lactic acid glycolic acid high polymer (PLGA) having good biocompatibility and broad biodegradability.
  • PLGA lactic acid glycolic acid high polymer
  • the degradation products of PLGA, lactic acid and glycolic acid can be quickly eliminated by the human body.
  • the degradation ability of the polymer can be extended from several months to several years depending on its molecular weight and composition (Lewis, "Controlled release of bioactive agents form lactide/glycolide polymer," in: M. Chasin and R. Langer (Eds.), Biodegradable Polymers as Drug Delivery Systems (Marcel Dekker: New York, 1990), pp. 1-41)).
  • a safe and effective amount of the active ingredient of the present invention is applied to a mammal (e.g., a human) in need of treatment wherein the dosage is a pharmaceutically effective effective dosage for a 60 kg body weight.
  • the dose per administration is usually 0.01 to 300 mg, preferably 0.5 to 100 mg.
  • specific doses should also consider factors such as the route of administration, the health of the patient, etc., which are within the skill of the skilled physician.
  • Vialinin A (an inhibitor of USP4) is administered at a dose of from 1 to 100 ng/kg body weight, preferably from 5 to 50 ng/kg body weight, more preferably 10 ng/kg body weight.
  • compositions for modulating RORyt, FOXP3, IL-17A, IL-17F, IL-21, IL-23R and IL-2 activity in a ubiquitination pathway-associated factor, agonist or antagonist thereof Use of the ubiquitination pathway-related factor selected from: USP4/USP17, a signal factor that induces USP4/USP17 expression or alters its nuclear localization, and/or their coding sequence; and/or the ubiquitin An agonist or antagonist of a pathway-associated factor.
  • the regulation of ROR ⁇ t, FOXP3, IL-17A, IL-17F, IL-21, IL-23R, and IL-2 activity may be positive or negative regulation, wherein the ubiquitin Pathway-associated factors or agonists thereof are used to positively regulate ROR ⁇ t, IL-17A, IL-17F, IL-21, IL-23R and IL-2 activities and negatively regulate FOXP3 activity, antagonism of ubiquitination pathway-associated factors
  • the agents are used to negatively regulate RORyt, IL-17A, IL-17F, IL-21, IL-23R and IL-2 activities and positively regulate FOXP3 activity.
  • the antagonist is shUSP4, shUSP17.
  • the antagonist is a USP4 inhibitor (4,4",5',6'-tetrahydroxy[1,1':4',1"-terphenyl]-2',3'-diyl ester benzeneacetic acid).
  • the pro-inflammatory cytokine is selected from the group consisting of IL-17 and IL-6.
  • the use is a use of a ubiquitination pathway-related factor in the preparation of a composition that positively modulates ROR ⁇ t activity, wherein the ubiquitination pathway-related factor is selected from the group consisting of: USP4/USP17, induction USP4/USP17 expresses or alters its nuclear factor-localized signaling factor, and/or an agonist or antagonist of the ubiquitination pathway-associated factor.
  • the activity disorder is hyperactivity or activity is too low.
  • the correlation is related to RORyt, FOXP3, IL-17A, IL-17F, IL-21, IL-23R and IL-2 activity.
  • USP4/USP17 protein-specific shRNA can inhibit IL-17A, IL-17F, IL-21, IL-23R and IL-2 mRNA expression and promote FOXP3 mRNA expression.
  • the composition further comprises a pharmaceutically, hygienic or immunologically acceptable carrier.
  • composition for modulating the activity of RORyt, FOXP3, IL-17A, IL-17F, IL-21, IL-23R and IL-2 comprising:
  • ubiquitination pathway-related factors selected from the group consisting of USP4/USP17, a signal factor that originally induces USP4/USP17 expression or alters its nuclear localization, and/or their coding sequence; and/ Or an agonist or antagonist of the ubiquitination pathway-related factor.
  • the composition is for the treatment or prevention of dysregulation of activity with ROR ⁇ t, FOXP3, IL-17A, IL-17F, IL-21, IL-23R and IL-2 (ie, activity is too high or activity is too low) a related disease or condition or as a vaccine adjuvant.
  • the composition further comprises one or more additional active substances that modulate RORyt, FOXP3, IL-17A, IL-17F, IL-21, IL-23R and IL-2.
  • the proto-oncogene protein USP4/USP17 reduces ubiquitination associated with RORyt degradation.
  • the content of the conditioning factor in the composition is from 0.05 to 99.5% by weight, preferably from 0.1 to 95% by weight, more preferably from 1 to 90% by weight, still more preferably from 5 to 80% by weight.
  • the composition is an injection, a tablet, a granule, a powder or a capsule.
  • a method of modulating the activity of RORyt, FOXP3, IL-17A, IL-17F, IL-21, IL-23R and IL-2 comprising administering one or more a ubiquitination pathway-related factor selected from the group consisting of USP4/USP17, a signal factor that induces USP4/USP17 expression or alters its nuclear localization, and/or their coding sequence; and/or the ubiquitination pathway-associated factor An agonist or antagonist.
  • the present invention still further provides a method of treating or preventing a disease or condition associated with dysregulation of RORyt, FOXP3, IL-17A, IL-17F, IL-21, IL-23R and IL-2 activity,
  • the method comprises administering to a subject in need of such treatment or prevention an effective amount of one or more ubiquitination pathway-related factors selected from the group consisting of USP4/USP17, a signal that induces USP4/USP17 expression or alters its nuclear localization.
  • Factores, and/or their coding sequences; and/or agonists or antagonists of the ubiquitination pathway-related factors are examples of the ubiquitination pathway-related factors.
  • the method is further for increasing the immunogenicity of the vaccine.
  • IL-6 can be used to promote deubiquitinating enzymes from the cytoplasm into the nucleus.
  • Deubiquitinating enzyme can enhance the stability of ROR ⁇ t and thereby increase the activity and differentiation of helper T cells.
  • the experimental methods in the following examples which do not specify the specific conditions can be carried out by conventional methods in the art, for example, refer to "Molecular Cloning Experimental Guide” (Third Edition, New York, Cold Spring Harbor Laboratory Press, New York: Cold Spring Harbor) Laboratory Press, 1989) or in accordance with the conditions recommended by the supplier.
  • the sequencing method of DNA is a routine method in the art, and can also be provided by a commercial company for testing.
  • the experimental materials used in the present invention are all available from commercially available sources.
  • N-terminal FLAG-tagged ROR ⁇ t, HA-tagged USP4, Myc-tagged USP17 and other plasmids and lentiviral packaging vector plasmids were cloned (see reference Liu, X.). ,Li,H.,Zhong,B.,Blonska,M.,Gorjestani,S.,Yan,M.,Tian,Q.,Zhang,DE,Lin,X.,and Dong,C.(2013)USP18inhibits NF -kappaB and NFAT activation during Th17differentiation by deubiquitinating the TAK1-TAB1 complex. The Journal of experimental medicine 210, 1575-1590).
  • USP4 USP17 gene was amplified from human peripheral blood mononuclear cell cDNA library.
  • the primers were designed according to the sequence downloaded by Genbank as follows:
  • Flag antibody (M2) was purchased from Sigma.
  • ROR ⁇ t antibody was purchased from eBioscience.
  • USP4, USP17 antibody was purchased from Sigma.
  • His antibody was purchased from SAB.
  • HRP-conjugated anti-mouse and anti-rabbit secondary antibodies were purchased from Promega.
  • Human HEK293T (purchased from the Chinese Academy of Sciences Cell Bank (catalog number: GNHu17)) in DMEM (Dulbecco's modified Eagle's medium) containing 10% FBS, 100 units/ml of streptomycin at 37 ° C, 5% CO 2 to cultivate.
  • DMEM Dulbecco's modified Eagle's medium
  • FLAG-ROR ⁇ t–Jurkat T cells (ROR ⁇ t stably expressed lymphocyte strains, produced and preserved by our laboratory) contain 10% FBS, 100 units/ml penicillin, 100 units/ml non-essential amino acids and 100 units/ In 1640 medium of sodium pyruvate, the cells were cultured at 37 ° C under 5% CO 2 .
  • HEK293T was transfected with polyethyleneimine PEI (Polyethylenimine) (according to the operation) The book is carried out), and the sample is analyzed after 48 hours of transfection.
  • Jurkat T was transfected with an electric shock method, see the electric shock method for Jurkat conditions.
  • the human embryonic kidney cell line HEK293T was co-transfected with PLKO.1, dR8.9 and VSV-G, and the cell culture supernatant was collected 48 and 72 hours after transfection.
  • the shUSP primer sequence is designed as follows:
  • the shCK primer sequence is as follows:
  • the USP4 inhibitor 4,4",5',6'-tetrahydroxy[1,1':4',1"-terphenyl]-2',3'-diphenyl phenylacetic acid was purchased from R&D.
  • TGF ⁇ , IL6, IL-23 and IL-1 ⁇ factors were purchased from Apotech.
  • MG132 was purchased from Merck.
  • Protein AG beads Protein AG-beads
  • RIPA buffer (20 mM Tris/HCL pH 7.5, 150 mM NaCl, 1% NP-40, 0.5% Na-DOC, 1 mM EDTA and protease inhibitor 1 mM PMSF, 1 ⁇ Cocktail, phosphatase inhibitor 1 mM Na 3 VO 4 , 1 mM NaF) lysed the cells.
  • the cell lysate was first incubated with primary antibody for 1 hour, and then agarose beads conjugated with Protein A/G were added for 1 hour. After three washes with RIPA buffer, the bound proteins were detected by SDS-PAGE.
  • the protein sample was electrophoresed by SDS-PAGE protein, transferred to a nitrocellulose membrane, blocked with 5% skim milk powder TBST for one hour, added with primary antibody for one hour, and then HRP-conjugated secondary antibody was incubated for one hour.
  • the ECL substrate is exposed to color.
  • USP4 mutant C331A USP17 mutant C89S was obtained by mutant PCR (see references Zhu, S., Pan, W., Shi, P., Gao, H., Zhao, F., Song, X., Liu, Y). .,Zhao,L.,Li,X.,Shi,Y.,and Qian,Y.(2010)Modulation of experimental autoimmune encephalomyelitis through TRAF3-mediated suppression of interleukin 17receptor signaling. The Journal of experimental medicine 207,2647-2662 ).
  • Example 1 USP4 is highly expressed in Th17 and affects the stability of its important transcription factor ROR ⁇ t.
  • CD45RA+CD4+naive T cells were sorted from human peripheral blood cells (PBMC) by flow cytometry (FACS), and different helper T cell subsets and inducible regulation were obtained under different helper T cell induction conditions.
  • Sex T cells iTreg
  • extract RNA for specific primer real-time fluorescent quantitative PCR q-RTPCR
  • WB Western blotting
  • Naive T cells were induced for 7 days under Th17 induction conditions, and incubated with USP4 gene knockdown virus (puromycin resistance) overnight. After transfusion, 72 hours after infection, puromycin was added for one week, and cells were collected for q- RTPCR and immunoblot detection with anti-USP4 and anti-ROR ⁇ t antibodies. The results are shown in Fig. 1C and D. It can be seen from Fig.
  • USP4 affects the stability of the important transcription factor ROR ⁇ t of Th17 cells.
  • Increasing the content of USP4 in cells can enhance the stability of ROR ⁇ t, while the stability of ROR ⁇ t is significantly decreased after the decrease of USP4 content, and affects the cytokines of Th17 cells. expression.
  • naive T cells were induced for 7 days under Th17 induction conditions, and then the cells were collected and lysed by RIPA buffer, and then co-immunoprecipitated with USP4 antibody, and then immunoblotted with anti-USP4 and anti-ROR ⁇ t antibodies.
  • endogenous USP4 was able to interact with ROR ⁇ t in Th17 cells, and the results showed that USP4 could interact with ROR ⁇ t.
  • HA-USP4 or its enzyme-activated mutant Ser311A mutant was co-transfected into HEK293T cells with FLAG-ROR ⁇ t. After 48 hours, the protein synthesis inhibitor imine cyclohexanone (CHX) was treated in a time-sharing period, and the cells were harvested and lysed with HA and FLAG and other corresponding antibodies were used for immunoblot analysis. As a result, as shown in Fig.
  • HA-USP4 and FLAG-ROR ⁇ t and His-ubiquitin or its mutant were co-transfected into HEK 293T cells, cells were harvested 48h and mutated with 8M urea and then labeled with nickel beads (beads) His (ie His-pull down assay) was combined with FLAG and other corresponding antibodies for immunoblot analysis.
  • USP4 can remove the ubiquitination modification associated with ROR ⁇ tK48, while the K63-related ubiquitination modification does not change.
  • the results show that USP4 can remove the ubiquitination modification associated with degradation of specific ROR ⁇ t.
  • FLAG-ROR ⁇ t-Jurkat stable strain was stimulated with USP4 inhibitor (20 nM) for 4 hours, and non-stimulated and FLAG-Jurkat control, cells were collected and lysed, then co-immunoprecipitated with FLAG, and then ubiquitin was used.
  • Antibodies and anti-USP4 and anti-FLAG antibodies were used for immunoblot analysis.
  • USP4 can remove endogenous ubiquitination of specific ROR ⁇ t.
  • the results show that USP4 can remove endogenous ubiquitination modification of specific ROR ⁇ t, and this process is USP4-dependent.
  • IL-17A luciferase promoter reporter gene 600-0bp
  • renilla control
  • different gradients of HA-USP4 and FLAG-ROR ⁇ t were co-transfected into HEK 293T cells, and the luciferase reporter gene was collected at 48 h.
  • the supernatant was added to the reaction solution and the blocking solution, and the fluorescence value was measured, and then HA and FLAG and other corresponding antibodies were used for immunoblot analysis.
  • the results are shown in Fig. 3A.
  • the abscissa is the cell treated with different treatment
  • the ordinate is the intensity of luciferase activity. It can be seen from the figure that USP4 promotes ROR ⁇ t-induced interleukin-17A transcription in a dose-dependent manner. The results show that USP4 can promote ROR ⁇ t-induced transcription and production of interleukin-17A.
  • HEK 293T cells were transfected into USP4 gene knockdown plasmid (puromycin resistance), transfected and transfected for 72 hours after transfection for one week. Cells were passaged and transferred to IL-17A luciferase promoter reporter gene ( -600-0bp), renilla (control) and FLAG-ROR ⁇ t, cells were harvested 48 hours later for fluorescence measurement and immunoblot detection with the corresponding antibodies. The results are shown in Fig. 3B, C. It can be seen in Fig. 3B that ROR ⁇ t induces down-regulation of interleukin-17A transcription after knocking down USP4, and the electrophoresis results in Fig. 3C show that the protein expression of ROR ⁇ t is also significantly reduced after knocking down USP4. . The above results show that USP4 is indispensable for promoting ROR ⁇ t-induced transcription and production of interleukin-17.
  • IL-17A luciferase promoter reporter gene 600-0bp
  • renilla control
  • PMA and inomycin myosin
  • the cells were collected and lysed with luciferase reporter lysate, and the supernatant was added to the reaction solution and the blocking solution to measure the fluorescence value, and then immunoblot analysis was performed using USP4 and FLAG and other corresponding antibodies.
  • Figure 3D shows that after activation of the TCR signal, USP4 can promote ROR ⁇ t-induced interleukin-17 transcription, while USP4 inhibitors can inhibit this effect;
  • Figure 3E shows that USP4 is able to stabilize ROR ⁇ t and incorporate USP4 inhibition.
  • the level of ROR ⁇ t protein decreased after the agent.
  • the result shows: in T cells Under the action of TCR signaling pathway, USP4 can promote the transcription and production of interleukin-17 induced by ROR ⁇ t.
  • Example 4 IL-6 promotes ROR ⁇ t-induced interleukin-17 by altering the nuclear localization of USP4 Transcription and production.
  • the IL-17A luciferase promoter reporter gene (-600-0bp) and renilla (control) were co-transfected into FLAG-ROR ⁇ t-Jurkat or FLAG-Jurkat cells, and 36h was replaced with fresh culture solution (P/I) overnight. After adding TGF ⁇ (1 ng/ml) and IL-6 (20 ng/ml) for 8 hours, the cells were collected and lysed with luciferase reporter lysate. The supernatant was added to the reaction solution and the blocking solution was added to measure the fluorescence value, and then USP4 was used. Immunoblot analysis was performed with FLAG and other corresponding antibodies. The results are shown in Figure 4A. It can be seen from the figure that IL-6 enhances the transcription of interleukin-17A induced by RORyt by USP4. The results show that IL-6 enhances the promotion of ROR ⁇ t-induced interleukin-17A transcription by USP4.
  • FLAG-ROR ⁇ t-Jurkat or FLAG-Jurkat cells were incubated with USP4 gene knockdown virus (puromycin resistance) overnight. After transfusion, 72 days after infection, add puromycin for one week, then transfer to IL-17A for luciferase initiation. Sub-reporter gene (-600-0bp), renilla (control), after 36h, fresh liquid was added to (P/I) overnight, TGF ⁇ (1ng/ml) and IL-6 (20ng/ml) were added to stimulate the cells for 8h.
  • USP4 gene knockdown virus puromycin resistance
  • luciferase reporter lysate was lysed, and the supernatant was added to the reaction solution and the blocking solution, and the fluorescence was measured, and then subjected to immunoblotting using USP4 and FLAG and other corresponding antibodies.
  • the results are shown in Fig. 4B, C, and D. It can be seen from Fig. B that after knocking down USP4, IL-6 stimulation does not enhance ROR ⁇ t-induced interleukin-17A transcription. From Fig. C, it can be seen that knocking down USP4 The expression of ROR ⁇ t protein was decreased in the post-stable strain.
  • FLAG-ROR ⁇ t-Jurkat cells were added (P/I) overnight, stimulated with different treatments of TGF ⁇ (1 or 5 ng/ml) and IL-6 (20 ng/ml) for 8 h.
  • the cells were harvested with paraformaldehyde for 30 min, 1%.
  • BSA was incubated with the corresponding antibody of USP4 for 1 h, washed with PBS three times, then incubated with fluorescent secondary antibody (red), DAPI (blue) for 1 h, and washed with PBS three times for immunofluorescence experiments.
  • the results are shown in Fig. 4E, F.
  • Example 5 USP4 inhibitors can impair Th17 cell differentiation and a rheumatoid heart dominated by Th17 High expression in dirty samples.
  • CD4+ T cells were enriched in the peripheral blood of rheumatic heart disease patients and healthy controls, and then subjected to qRT-PCR analysis using specific primers. The results are shown in Figure 5D. It can be seen from the figure that the transcription level of USP4 is significantly elevated in rheumatic heart disease samples. The results show that USP4 is highly expressed in Th17-dominant rheumatic heart disease samples.
  • Example 6 Deubiquitinating enzymes USP2, USP4, USP12, USP14, USP39 enhance ROR ⁇ t-mediated
  • the transcriptional activity of the Il17a promoter, USP2, USP4, USP17 is effective in removing the ubiquitination of RORyt.
  • Myc-DUBs, FLAG-ROR ⁇ t and HA-Ubiquitin were co-transfected into HEK 293T cells.
  • the cells were harvested for 48 hours, then lysed by RIPA buffer and then anti-Flag antibody was used for immunoprecipitation, and then the corresponding antibodies were used for immunoblotting.
  • Fig. 6B it can be seen from Fig. 6B that the addition of USP2 or USP4 or USP17 significantly reduces the level of ubiquitination of ROR ⁇ t compared to the second lane without addition of deubiquitinating enzyme.
  • USP2, USP4, USP17 can effectively Removal of ubiquitination of RORyt.
  • IL-17A luciferase promoter reporter gene 600-0bp
  • renilla control
  • PMA and inomycin myomycin
  • the cells were collected and lysed with luciferase reporter lysate, and the supernatant was added to the reaction solution and the blocking solution to measure the fluorescence value.
  • Fig. 6D It can be seen from the figure that USP17 is ROR after T cell activation. The enhanced effect of induced interleukin-17A transcription is dose dependent. The results show that USP17 can promote ROR ⁇ t-induced transcription and production of interleukin-17A under the action of TCR signaling pathway in T cells.
  • Myc-USP17 and FLAG-ROR ⁇ t were co-transfected into HEK 293T cells.
  • the cells were harvested 48h later and then lysed by RIPA buffer.
  • the anti-Myc antibody or anti-Flag antibody was used for immunoprecipitation, and then the corresponding antibody was used for immunoblotting.
  • Fig. 7A it can be seen from the figure that USP17 and ROR ⁇ t interact.
  • naive T cells were induced under Th17 induction conditions for 7 days, then the cells were collected and lysed by RIPA buffer, then co-immunoprecipitated with anti-USP17 antibody, and then immunoblotted with the corresponding antibodies.
  • the results are shown in Figure 7B. It can be seen that endogenous USP17 and ROR ⁇ t interact in Th17 cells. This result shows that USP17 can interact with ROR ⁇ t.
  • ROR ⁇ t 1-75aa, 10-75aa and 248-497aa three-section truncation mutants and Myc-USP17 were overexpressed in HEK293T, immunoprecipitated with anti-Myc antibody, and finally detected by immunoblotting.
  • the results are shown in Figure 7C. D, it can be seen from Figure C that ROR ⁇ t contains two domains: a DNA binding domain and a ligand binding domain. It can be seen from Figure D that USP17 can interact with the two domains of ROR ⁇ t. The results show that both domains of USP17 and ROR ⁇ t can interact.
  • Myc-ROR ⁇ t and FLAG-Ubiquitin were co-transfected into HEK 293T cells.
  • the cells were harvested for 48 hours, then lysed by RIPA buffer and then co-immunoprecipitated with anti-Myc antibody, and then immunoblotted with the corresponding antibody.
  • the results are shown in Figure 9A. It can be seen from the figure that ROR ⁇ t can be ubiquitinated and ubiquitination can occur at both K48 and K63 positions. The results show that ROR ⁇ t can be ubiquitinated and ubiquitination can occur at both K48 and K63 positions.
  • Flag-ROR ⁇ t, Myc-USP17 and His-Ubiquitin were transiently expressed in HEK293T cells, and the precipitate was purified using Ni-NTA (nickel triacetate), and finally detected by immunoblotting. The results are shown in Fig. 9B. It can be seen that USP17 relies on its enzymatic activity to deubiquitinate ROR ⁇ t. The results show that USP17 can deubiquitinate ROR ⁇ t, while its enzyme-activated mutant (USP17C89S) has no function.
  • Flag-ROR ⁇ t, Myc-USP17 and His-Ubiquitin or their mutants (K48only, K63only), the two mutants refer to ubiquitin itself except for the lysine at position 48 or 63, and the others are all mutated to arginine.
  • the HEK 293T cells were co-transferred and purified by Ni-NTA (nickel triacetate). The experimental results are shown in Figure 9C. It can be seen from the figure that USP17 mainly mediates the deubiquitination of the ROR ⁇ t K48 site. The results showed that USP17 mainly mediates deubiquitination of the ROR ⁇ t K48 site.
  • Example 10 Down-regulation of USP17 in Th17 cells reduces ROR ⁇ t protein levels and affects Th17 correlation Transcriptional levels of cytokines.
  • AAGCAGGAAGATGCCCATGAA (shUSP17-1, SEQ ID NO.: 14);
  • AAGTCACCACTCTCATGTGAG (shUSP17-2, SEQ ID NO.: 15);
  • the FLAG-ROR ⁇ t-Jurkat stably transfected cells were incubated with USP17 gene silencing virus (puromycin antibody) overnight. After transfection, the cells were added to puromycin for 72 weeks after infection, and the cells were collected and immunoblotted with the corresponding antibodies. The results are shown in Fig. 10B. It can be seen from the figure that gene silencing of USP17 can reduce the expression of ROR ⁇ t in stably transformed strains. The results showed that USP17 affects the stability of ROR ⁇ t protein in FLAG-ROR ⁇ t-Jurkat stably transfected cells.
  • Naive T cells were induced for 7 days under Th17 induction conditions, and incubated with USP17 gene silencing virus (puromycin resistance) overnight. After transfusion, 72 days after infection, puromycin was added for one week. Cells were harvested for q-RTPCR and immunoblotted with the corresponding antibodies. The results are shown in Figure 10C, D. It can be seen from Figure C that gene silencing of USP17 can reduce the expression of ROR ⁇ t in Th17 cells. From Figure D, it can be seen that the transcription level of Th17-associated cytokine IL-17A after gene silencing USP17 Down. The results showed that USP17 affects the stability of the R17 ⁇ protein of Th17 cells and the important transcription factor ROR ⁇ t.
  • Example 11 USP17 transcription levels were significantly elevated in patients with systemic lupus erythematosus.
  • Example 12 Deubiquitinating enzyme antagonists have significant therapeutic effects on autoencephalomyelitis.
  • mice were injected with pertussis toxin in the tail vein, and the MOG peptide (purchased from Jill Biochemical (Shanghai) Co., Ltd.) was subcutaneously administered to induce experimental neoencephalomyelitis.
  • Vialinin A (inhibitor of USP4) was intraperitoneally injected on days 9, 12, and 15, respectively, at a dose of 10 ng/kg of mouse body weight, and the control group was injected with the same amount of solvent (PBS containing 5% DMSO). The disease status of the mice was observed, and the mice were sacrificed on the 25th day for experimental analysis.
  • Figure 12 shows the therapeutic effect of Vialinin A on its own encephalomyelitis, wherein
  • Panel B shows the disease score. The results showed that the control group started on the 10th day, and then the disease developed rapidly and entered the plateau on the 19th day. There was no significant difference between the drug-administered group and the control group in the early stage of the disease. In the 18 to 21 days with severe disease, the drug-administered group was significantly better than the control group;
  • TRAF6 inhibits Th17 differentiation and TGF-beta-mediated Suppression of IL-2.Blood 115,4750-4757

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

L'invention concerne l'utilisation de facteurs associés à la voie d'ubiquitination pour réguler le fonctionnement de cellules T auxiliaires. En particulier, l'invention concerne l'utilisation d'un facteur lié à la voie d'ubiquitination, un agoniste ou un antagoniste de celui-ci dans la préparation d'une préparation ou d'un kit de régulation des cellules RORγt et des cellules T auxiliaires, le facteur lié à la voie d'ubiquitination étant sélectionné parmi des protéines telles que USP4, USP17, etc. codées par un proto-oncogène de la famille des protéines de désubiquitination.
PCT/CN2015/084078 2014-07-23 2015-07-15 Utilisation de facteurs associés à la voie d'ubiquitination pour réguler le fonctionnement de cellules t auxiliaires Ceased WO2016011906A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201410353643.4 2014-07-23
CN201410353643.4A CN105327350A (zh) 2014-07-23 2014-07-23 泛素化途径相关因子在调控辅助性t细胞功能中的应用

Publications (1)

Publication Number Publication Date
WO2016011906A1 true WO2016011906A1 (fr) 2016-01-28

Family

ID=55162504

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2015/084078 Ceased WO2016011906A1 (fr) 2014-07-23 2015-07-15 Utilisation de facteurs associés à la voie d'ubiquitination pour réguler le fonctionnement de cellules t auxiliaires

Country Status (2)

Country Link
CN (1) CN105327350A (fr)
WO (1) WO2016011906A1 (fr)

Cited By (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019043208A1 (fr) 2017-09-04 2019-03-07 F. Hoffmann-La Roche Ag Dihydroquinolinones
WO2019043217A1 (fr) 2017-09-04 2019-03-07 F. Hoffmann-La Roche Ag Dihydrobenzimidazolones
WO2019043214A1 (fr) 2017-09-04 2019-03-07 F. Hoffmann-La Roche Ag Glutarimide
WO2019121562A1 (fr) 2017-12-18 2019-06-27 F. Hoffmann-La Roche Ag Inhibiteurs bifonctionnels avec egfr ayant une fraction d'ubiquitine ligase e3
WO2019149922A1 (fr) 2018-02-05 2019-08-08 F. Hoffmann-La Roche Ag Composés qui provoquent la dégradation de l'egfr, destinés à être utilisés contre le cancer
EP3556760A1 (fr) 2018-04-19 2019-10-23 F. Hoffmann-La Roche AG Spirocomposés
EP3578561A1 (fr) 2018-06-04 2019-12-11 F. Hoffmann-La Roche AG Spirocomposés
US10690656B2 (en) 2015-02-27 2020-06-23 Mission Therapeutics Limited Methods of screening and treatment with USP4 inhibitors
WO2020181232A1 (fr) 2019-03-06 2020-09-10 C4 Therapeutics, Inc. Composés hétérocycliques pour traitement médical
WO2021127561A1 (fr) 2019-12-20 2021-06-24 C4 Therapeutics, Inc. Composés d'isoindolinone et d'indazole pour la dégradation de l'egfr
WO2023283130A1 (fr) 2021-07-04 2023-01-12 Newave Pharmaceutical Inc. Dérivés d'isoquinoléine en tant que modulateurs d'egfr mutants et leurs utilisations
US11584748B2 (en) 2018-04-16 2023-02-21 C4 Therapeutics, Inc. Spirocyclic compounds
CN116271007A (zh) * 2022-12-26 2023-06-23 浙江大学 一种用于治疗炎症性肠病的药物
CN118161490A (zh) * 2024-05-10 2024-06-11 昆明医科大学 一种去泛素化酶抑制剂在制备预防或者治疗炎症药物中的应用

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105802945B (zh) * 2016-04-05 2019-05-03 上海市东方医院 泛素特异性蛋白酶49的用途
CN108504692B (zh) * 2018-03-26 2021-07-23 安徽大学 一种基因敲除cho细胞株的构建方法及其在治疗性重组蛋白表达中的应用
CN110004228B (zh) * 2019-04-03 2023-05-23 清华大学深圳研究生院 一种与乳腺癌分子分型相关的诊断标志物及其用途
CN111388675B (zh) * 2020-04-15 2021-06-01 浙江大学 Yod1基因在制备白血病诱导分化治疗药物中的应用
CN111588840A (zh) * 2020-05-26 2020-08-28 广东龙帆生物科技有限公司 组蛋白去泛素化酶在制备治疗系统性红斑狼疮药物的应用
CN114699394B (zh) * 2022-05-24 2022-09-13 中山大学附属第一医院 用于肝癌放疗增敏的药物组合物及其应用
WO2024178965A1 (fr) * 2023-02-27 2024-09-06 Wuhan University Modulation de la signalisation pd-1 pour le traitement de maladies

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102309757A (zh) * 2010-07-09 2012-01-11 中国科学院上海巴斯德研究所 Foxp3及调节性ｔ细胞的调节因子及其应用
JP2012036150A (ja) * 2010-08-10 2012-02-23 Aomori Univ Of Health & Welfare 抗腫瘍剤、カスパーゼ阻害剤、イボタケ属担子菌抽出物およびその製造方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2828404B1 (fr) * 2001-08-10 2005-07-15 Neovacs Superimmunogene composite a usage vaccinal bifonctionnel pour le traitement des maladies associees a un desordre tissulaire stromal
ATE478676T1 (de) * 2005-11-04 2010-09-15 Forhumantech Co Ltd Verfahren zur abgabe von fusionspolypeptid in eine zelle
EP1798232A1 (fr) * 2005-12-08 2007-06-20 Hybrigenics S.A. Inhibiteurs de la cysteine protease, compositions pharmaceutiques et applications therapeutiques
US8637560B2 (en) * 2007-07-18 2014-01-28 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Imidazolidinone compounds, methods to inhibit deubiquitination and methods of treatment
JP2013504586A (ja) * 2009-09-10 2013-02-07 メイヨ・ファウンデーション・フォー・メディカル・エデュケーション・アンド・リサーチ 脱ユビキチン化酵素およびユビキチン化ポリペプチドを調節するための方法および材料
EP2619184B1 (fr) * 2010-09-24 2018-05-23 The Regents of the University of Michigan Inhibiteurs de déubiquitinase et leurs procédés d'utilisation
EP2565186A1 (fr) * 2011-09-02 2013-03-06 Hybrigenics S.A. Inhibiteurs sélectifs et réversibles de la protéase 7 spécifique de l'ubiquitine
CN103768583B (zh) * 2014-01-02 2016-08-17 华侨大学 一种天然多种形态砷的提取液组合物的应用

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102309757A (zh) * 2010-07-09 2012-01-11 中国科学院上海巴斯德研究所 Foxp3及调节性ｔ细胞的调节因子及其应用
JP2012036150A (ja) * 2010-08-10 2012-02-23 Aomori Univ Of Health & Welfare 抗腫瘍剤、カスパーゼ阻害剤、イボタケ属担子菌抽出物およびその製造方法

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
HAN, LEI ET AL.: "The E3 Deubiquitinase USP 17 Is a Positive Regulator of Retinoic Acid-related Orphan Nuclear Receptor gammat (ROR gammat) in Th17 Cells", THE JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 289, no. 37, 12 September 2014 (2014-09-12), pages 25546 - 25555 *

Cited By (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10690656B2 (en) 2015-02-27 2020-06-23 Mission Therapeutics Limited Methods of screening and treatment with USP4 inhibitors
US12091397B2 (en) 2017-09-04 2024-09-17 C4 Therapeutics, Inc. Dihydroquinolinones for medical treatment
WO2019043217A1 (fr) 2017-09-04 2019-03-07 F. Hoffmann-La Roche Ag Dihydrobenzimidazolones
WO2019043214A1 (fr) 2017-09-04 2019-03-07 F. Hoffmann-La Roche Ag Glutarimide
US11787802B2 (en) 2017-09-04 2023-10-17 C4 Therapeutics, Inc. Dihydrobenzimidazolones for medical treatment
US11802131B2 (en) 2017-09-04 2023-10-31 C4 Therapeutics, Inc. Glutarimides for medical treatment
US11401256B2 (en) 2017-09-04 2022-08-02 C4 Therapeutics, Inc. Dihydroquinolinones for medical treatment
WO2019043208A1 (fr) 2017-09-04 2019-03-07 F. Hoffmann-La Roche Ag Dihydroquinolinones
US12365681B2 (en) 2017-09-04 2025-07-22 C4 Therapeutics, Inc. Dihydrobenzimidazolones for medical treatment
US11254672B2 (en) 2017-09-04 2022-02-22 C4 Therapeutics, Inc. Dihydrobenzimidazolones for medical treatment
WO2019121562A1 (fr) 2017-12-18 2019-06-27 F. Hoffmann-La Roche Ag Inhibiteurs bifonctionnels avec egfr ayant une fraction d'ubiquitine ligase e3
WO2019149922A1 (fr) 2018-02-05 2019-08-08 F. Hoffmann-La Roche Ag Composés qui provoquent la dégradation de l'egfr, destinés à être utilisés contre le cancer
US12227504B2 (en) 2018-04-16 2025-02-18 C4 Therepeutics, Inc. Spirocyclic compounds
US11584748B2 (en) 2018-04-16 2023-02-21 C4 Therapeutics, Inc. Spirocyclic compounds
EP3556760A1 (fr) 2018-04-19 2019-10-23 F. Hoffmann-La Roche AG Spirocomposés
EP3578561A1 (fr) 2018-06-04 2019-12-11 F. Hoffmann-La Roche AG Spirocomposés
WO2019236483A1 (fr) 2018-06-04 2019-12-12 C4 Therapeutics, Inc. Composés spirocycliques
EP4470618A2 (fr) 2019-03-06 2024-12-04 C4 Therapeutics, Inc. Composés hétérocycliques pour traitement médical
WO2020181232A1 (fr) 2019-03-06 2020-09-10 C4 Therapeutics, Inc. Composés hétérocycliques pour traitement médical
US12528797B2 (en) 2019-03-06 2026-01-20 C4 Therapeutics, Inc. Heterocyclic compounds for medical treatment
WO2021127561A1 (fr) 2019-12-20 2021-06-24 C4 Therapeutics, Inc. Composés d'isoindolinone et d'indazole pour la dégradation de l'egfr
EP4681715A2 (fr) 2019-12-20 2026-01-21 C4 Therapeutics, Inc. Composés d'isoindolinone et d'indazole pour la dégradation de l'egfr
WO2023283130A1 (fr) 2021-07-04 2023-01-12 Newave Pharmaceutical Inc. Dérivés d'isoquinoléine en tant que modulateurs d'egfr mutants et leurs utilisations
CN116271007A (zh) * 2022-12-26 2023-06-23 浙江大学 一种用于治疗炎症性肠病的药物
CN118161490A (zh) * 2024-05-10 2024-06-11 昆明医科大学 一种去泛素化酶抑制剂在制备预防或者治疗炎症药物中的应用

Also Published As

Publication number Publication date
CN105327350A (zh) 2016-02-17

Similar Documents

Publication Publication Date Title
WO2016011906A1 (fr) Utilisation de facteurs associés à la voie d'ubiquitination pour réguler le fonctionnement de cellules t auxiliaires
Wang et al. Mechanism by which TRAF6 participates in the immune regulation of autoimmune diseases and cancer
AU2002309829B2 (en) Use of HMG fragment as anti-inflammatory agents
US8501173B2 (en) Antibodies to high mobility group-1(HMGB1) B-box polypeptides
KR102359396B1 (ko) 혈관 신생 억제 활성을 가지는 펩티드 및 이를 포함하는 조성물
Saulite et al. Sézary syndrome and atopic dermatitis: comparison of immunological aspects and targets
EP2591797A1 (fr) Facteur de régulation de foxp3 et de lymphocytes t régulateurs et son utilisation
CN106659757A (zh) 白介素2的超级激动剂、部分激动剂和拮抗剂
CN113286604B (zh) 治疗炎症性疾病的蛋白质
EP2519260A2 (fr) Nouveaux modulateurs de signalisation par trail
CN110974842A (zh) 鉴定用于治疗癌症的化合物的方法
Xu et al. USP25 stabilizes STAT6 to promote IL-4-induced macrophage M2 polarization and fibrosis
US20200399335A1 (en) Modified immunomodulatory peptide
CN108144049A (zh) 泛素化途径相关因子在调控调节性t细胞功能中的应用
US20210393740A1 (en) Ptprs and proteoglycans in rheumatoid arthritis
CN102901826A (zh) 人类潜在新细胞因子tmem98及其用途
US20110311558A1 (en) Recombinant Bone Marrow Stromal Antigen-2 in the Treatment of Autoimmune Diseases
US20140170108A1 (en) Compositions useful for the treatment of inflammatory disease or disorders
CN108295242A (zh) 用于预防和/或治疗银屑病药物组合物、cd317胞外段蛋白的应用
AU2007234583B2 (en) Use of HMG fragment as anti-inflammatory agents
CN115490768B (zh) Col1a1的表位肽及所述表位肽与热休克蛋白的复合物
CN105368847B (zh) 一种防治鸡球虫病的chp317基因、疫苗及其制备方法
CN113398270B (zh) 一种治疗骨巨细胞瘤的方法
US11571462B2 (en) Engineered CCL20 locked dimer polypeptide
EP3459551A1 (fr) Utilisation de trioxyde d'arsenic dans la prévention ou le traitement de maladies associées à l'activation du système d'interféron de type i

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 15824812

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 15824812

Country of ref document: EP

Kind code of ref document: A1